0000950170-22-003222.txt : 20220309 0000950170-22-003222.hdr.sgml : 20220309 20220309160546 ACCESSION NUMBER: 0000950170-22-003222 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220309 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220309 DATE AS OF CHANGE: 20220309 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mirum Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001759425 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831281555 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38981 FILM NUMBER: 22725421 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE, SUITE 1050 CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 650-667-4085 MAIL ADDRESS: STREET 1: 950 TOWER LANE, SUITE 1050 CITY: FOSTER CITY STATE: CA ZIP: 94404 8-K 1 mirm-20220309.htm 8-K 8-K
0001759425false00017594252022-03-092022-03-09

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 09, 2022

 

 

Mirum Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38981

83-1281555

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

950 Tower Lane

Suite 1050

 

Foster City, California

 

94404

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 650 667-4085

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.0001 per share

 

MIRM

 

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


Item 2.02 Results of Operations and Financial Condition.

On March 9, 2022, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter and year ended December 31, 2021. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

No.

 

Description

 

 

99.1

 

Press Release dated March 9, 2022

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

Mirum Pharmaceuticals, Inc.

 

 

 

 

 

Date: March 9, 2022

 

By:

 

/s/ Christopher Peetz

 

 

 

 

Christopher Peetz

 

 

 

 

President and Chief Executive Officer

 


EX-99.1 2 mirm-ex99_1.htm EX-99.1 EX-99.1

 

img233628718_0.jpg 

Exhibit 99.1

 

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

 

- Strong commercial launch underway with LIVMARLI® (maralixibat) oral solution; net product revenue of $3.1 million for the first quarter of launch, total 2021 company revenue of $19.1 million

 

- Expect at least $8.0 million in LIVMARLI net product sales in first quarter 2022

 

- Conference call to provide business updates today, March 9 at 1:30 p.m. PT/4:30 p.m. ET

 

FOSTER CITY, Calif. – March 9, 2022 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2021 and provided a business update.

 

“2021 marked a significant turning point for Mirum and the Alagille syndrome community. With a strong start to our launch of LIVMARLI, the first and only FDA-approved medication for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older, we achieved fourth quarter 2021 net product revenue of $3.1 million,” said Chris Peetz, president and chief executive officer at Mirum. “We expect continued growth in prescriptions and reimbursement as we unlock LIVMARLI’s potential both in the United States and globally. In addition to our growing topline, we look forward to generating data from all five of our late-stage pipeline indications over the coming two years.”

 

2021 Highlights

Fourth Quarter

Launched LIVMARLI in the United States, the first and only medicine approved for cholestatic pruritus in patients with Alagille syndrome one year of age and older.
Sold Rare Pediatric Disease Priority Review Voucher (PRV), granted by the U.S. Food and Drug Administration (FDA) in September 2021 in connection with the approval of LIVMARLI, for $110.0 million.
Presented late-breaking oral presentation on six-year natural history comparison with LIVMARLI showing event-free survival (p<0.0001) and transplant-free survival (p<0.0001) in patients with Alagille syndrome. Also presented analysis highlighting prognostic markers of event-free survival for patients with Alagille syndrome.
Publication in The Lancet highlights LIVMARLI ICONIC data demonstrating four-year durable and clinically meaningful improvements across multiple cholestasis parameters, including pruritus.
Presented data from the ICONIC and INDIGO studies showing the impact of LIVMARLI treatment response on changes in health-related quality of life measures among patients with Alagille syndrome and progressive familial intrahepatic cholestasis with BSEP deficiency (PFIC2).

Full Year

Received FDA approval for LIVMARLI for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.
Submitted marketing authorization application to the European Medicines Agency (EMA) for LIVMARLI for the treatment of cholestatic liver disease in patients with Alagille syndrome.
Entered into partnership and distribution agreements to accelerate the potential availability of LIVMARLI in key regions.

 

Additional Key Operational Updates

 

 


 

img233628718_0.jpg 

Announced today that on January 25, 2022, the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,229,647 with coverage through February 12, 2040. This patent is now also listed in the U.S. FDA publication, “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the “Orange Book,” further protecting LIVMARLI. The patent is supplemented by additional orange book listable patent grants and allowances with coverage to 2031 and 2032, respectively.
Partner GC Pharma submitted a pharmaceutical approval application to the Ministry of Food and Drug Safety in Korea for LIVMARLI for the treatment of cholestatic pruritus in patients with Alagille syndrome.
Launched expanded access program for patients with progressive familial intrahepatic cholestasis.

 

Financial Results

Total net product revenue from the sale of LIVMARLI for the fourth quarter and year ended December 31, 2021 was $3.1 million, compared to none for the fourth quarter and year ended 2020.
For the years ended December 31, 2021 and 2020, total licensing revenue was $16.0 million and none, respectively. There was no licensing revenue recorded for the fourth quarter ended December 31, 2021 and 2020.
Total operating expenses for the fourth quarter ended December 31, 2021 were $48.7 million, compared to $37.0 million for the fourth quarter of 2020. For the years ended December 31, 2021 and 2020, total operating expenses were $192.6 million and $104.3 million, respectively.
o
Research and development expenses for the fourth quarter ended December 31, 2021 were $27.8 million, compared to $29.7 million for the comparable prior-year period. For the years ended December 31, 2021 and 2020, research and development expenses were $131.4 million and $81.6 million, respectively. The increase in full year 2021 was primarily due to activities supporting the volixibat programs, collaboration funding for the Vivet program, development milestone fees, increased personnel costs including stock-based compensation, offset by a decrease in the expense associated with the LIVMARLI programs.
o
Selling, general and administrative (SG&A) expenses for the fourth quarter of 2021 were $19.0 million, compared to $7.2 million for the comparable prior-year period. For the years ended December 31, 2021 and 2020, SG&A expenses were $59.2 million and $22.7 million, respectively. SG&A investment increased in the fourth quarter of 2021 versus the fourth quarter of 2020, primarily due to an increase in expenses associated with commercial launch activities for LIVMARLI, including personnel and stock-based compensation expenses, and increased requirements of operating as a public company.
For the fourth quarter ended December 31, 2021, Mirum reported net income of $57.5 million, compared with a net loss of $37.2 million for the same period in 2020. For the year ended December 31, 2021, Mirum reported a net loss of $84.0 million, compared to a net loss of $103.3 million for the same period in 2020.
As of December 31, 2021, Mirum had cash, cash equivalents, restricted cash equivalents, and investments of $261.5 million.

 

Upcoming Anticipated Milestones

LIVMARLI (maralixibat)
o
Launch commercial early access programs in international markets for LIVMARLI in the first half of 2022.
o
Topline data from MARCH-PFIC Phase 3 clinical trial expected in the fourth quarter of 2022.
o
Alagille syndrome launch in Europe in the fourth quarter 2022, if approved by the EMA.

 

 


 

img233628718_0.jpg 

o
EMBARK Phase 2b clinical trial for biliary atresia currently enrolling; topline data anticipated in 2023.
Volixibat
o
Interim analyses expected for VISTAS Phase 2b clinical trial for primary sclerosing cholangitis in the fourth quarter of 2022.
o
First interim analysis expected for OHANA Phase 2b clinical trial for intrahepatic cholestasis of pregnancy in the fourth quarter of 2022.
o
Enrollment ongoing for VANTAGE Phase 2b clinical trial for primary biliary cholangitis; interim analysis expected in 2023.

 

Business Update Conference Call

 

Mirum will host a conference call today, March 9, 2022 at 1:30 p.m. PT/4:30 p.m. ET, to provide business updates. Join the call using the following details:

 

Conference Call Details:

U.S./Toll-Free: 833-927-1758

International: 646-904-5544

Passcode: 521837

 

You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.

 

About LIVMARLI® (maralixibat) oral solution

 

LIVMARLI® (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. Food and Drug Administration for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older and is the only FDA-approved medication to treat cholestatic pruritus associated with Alagille syndrome. For more information, please visit LIVMARLI.com.

 

LIVMARLI is currently being evaluated in late-stage clinical studies in other rare cholestatic liver diseases including progressive familial intrahepatic cholestasis (PFIC) and biliary atresia. LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS, PFIC and biliary atresia. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum’s clinical trials section on the company’s website.

 

IMPORTANT SAFETY INFORMATION

 

LIVMARLI can cause serious side effects, including:

 

Changes in liver tests. Changes in certain liver tests are common in patients with Alagille syndrome and can worsen during treatment with LIVMARLI. These changes may be a sign of liver injury and can be serious. Your healthcare provider should do blood tests before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen) or loss of appetite.

 

 

 


 

img233628718_0.jpg 

Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea, stomach pain, and vomiting during treatment. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you.

 

A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat. FSV deficiency is common in patients with Alagille syndrome but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment.

 

Other common side effects reported during treatment were bone fractures and gastrointestinal bleeding.

 

Prescribing information

 

About Volixibat

Volixibat is an oral, minimally absorbed agent designed to selectively inhibit the ileal bile acid transporter (IBAT). Volixibat may offer a novel approach in the treatment of adult cholestatic diseases by blocking the recycling of bile acids, through inhibition of IBAT, thereby reducing bile acids systemically and in the liver. Phase 1 and Phase 2 studies of volixibat demonstrated on-target fecal bile acid excretion, a pharmacodynamic marker of IBAT inhibition, in addition to decreases in LDL cholesterol and increases in 7αC4 which are markers of bile acid synthesis. Volixibat has been evaluated in more than 400 individuals across multiple clinical trials. The most common adverse events reported were mild to moderate gastrointestinal events observed in the volixibat groups.

 

Volixibat is currently being evaluated in Phase 2b studies for primary sclerosing cholangitis (VISTAS Phase 2b clinical trial), intrahepatic cholestasis of pregnancy (OHANA Phase 2b clinical trial), and primary biliary cholangitis (VANTAGE Phase 2b clinical trial).

 

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.

 

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 clinical trial for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

 

Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.

 

Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.

 

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.

 

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the expected continued growth in prescriptions and reimbursement through 2022, the ability for Mirum to reach transformational and value-generating milestones, the increased availability of LIVMARLI in key regions, the anticipated launch and timing of the expanded access

 

 


 

img233628718_0.jpg 

program for LIVMARLI in international markets, continued commercial success for LIVMARLI, the results, conduct and progress of Mirum’s ongoing and planned clinical trials for its product candidates and the regulatory approval path for its product candidates globally. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “will,” “anticipate,” “expect,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general, the impact of the COVID-19 pandemic, and the other risks described in Mirum’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

 

Mirum Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations Data

(in thousands, except share and per share amounts)

 

 

 

Three Months Ended December 31,

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(Unaudited)

 

 

 

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Product sales, net

 

$

3,138

 

 

$

 

 

$

3,138

 

 

$

 

License revenue

 

 

 

 

 

 

 

 

16,000

 

 

 

 

Total revenue

 

 

3,138

 

 

 

 

 

 

19,138

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

 

1,903

 

 

 

 

 

 

1,903

 

 

 

 

Research and development

 

 

27,775

 

 

 

29,726

 

 

 

131,428

 

 

 

81,605

 

Selling, general and administrative

 

 

19,035

 

 

 

7,225

 

 

 

59,220

 

 

 

22,691

 

Total operating expenses (1)

 

 

48,713

 

 

 

36,951

 

 

 

192,551

 

 

 

104,296

 

Loss from operations

 

 

(45,575

)

 

 

(36,951

)

 

 

(173,413

)

 

 

(104,296

)

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

65

 

 

 

168

 

 

 

366

 

 

 

1,559

 

Interest expense

 

 

(3,766

)

 

 

(335

)

 

 

(17,590

)

 

 

(335

)

Change in fair value of derivative liability

 

 

(1,149

)

 

 

 

 

 

(732

)

 

 

 

Other expense, net

 

 

(17

)

 

 

(83

)

 

 

(582

)

 

 

(192

)

Gain from sale of priority review voucher, net

 

 

108,000

 

 

 

 

 

 

108,000

 

 

 

 

Net income (loss) before provision for income taxes

 

 

57,558

 

 

 

(37,201

)

 

 

(83,951

)

 

 

(103,264

)

Provision for income taxes

 

 

12

 

 

 

2

 

 

 

37

 

 

 

6

 

Net income (loss)

 

$

57,546

 

 

$

(37,203

)

 

$

(83,988

)

 

$

(103,270

)

Net income (loss) per share, basic and diluted

 

 

 

 

 

 

 

$

(2.77

)

 

$

(4.09

)

Weighted-average shares of common stock outstanding, basic and diluted

 

 

 

 

 

 

 

 

30,321,722

 

 

 

25,251,968

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) Amounts include stock-based compensation as follows:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

2,095

 

 

$

1,467

 

 

$

9,888

 

 

$

5,129

 

Selling, general and administrative

 

 

3,397

 

 

 

2,112

 

 

 

13,128

 

 

 

7,425

 

Total stock-based compensation

 

$

5,492

 

 

$

3,579

 

 

$

23,016

 

 

$

12,554

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

img233628718_0.jpg 

Mirum Pharmaceuticals, Inc.

Selected Consolidated Balance Sheets Data

(in thousands)

 

 

 

December 31,
2021

 

 

December 31,
2020

 

 

 

 

 

 

 

 

Cash, cash equivalents, restricted cash equivalents, and investments

 

$

261,524

 

 

$

231,820

 

Working capital

 

 

123,996

 

 

 

217,888

 

Total assets

 

 

294,651

 

 

 

240,864

 

Accumulated deficit

 

 

(257,159

)

 

 

(173,171

)

Total stockholders' equity

 

 

120,212

 

 

 

172,095

 

 

Contacts

Investor Contacts:

Ian Clements, Ph.D.

ir@mirumpharma.com

 

Sam Martin

Argot Partners

ir@mirumpharma.com

 

Media Contact:

Erin Murphy

media@mirumpharma.com

 

 

 

 


GRAPHIC 3 img233628718_0.jpg GRAPHIC begin 644 img233628718_0.jpg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mirm-20220309_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 5 mirm-20220309_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.SCH 6 mirm-20220309.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document And Entity Information
Mar. 09, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 09, 2022
Entity Registrant Name Mirum Pharmaceuticals, Inc.
Entity Central Index Key 0001759425
Entity Emerging Growth Company true
Entity File Number 001-38981
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 83-1281555
Entity Address, Address Line One 950 Tower Lane
Entity Address, Address Line Two Suite 1050
Entity Address, City or Town Foster City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94404
City Area Code 650
Local Phone Number 667-4085
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period true
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol MIRM
Security Exchange Name NASDAQ
XML 8 mirm-20220309_htm.xml IDEA: XBRL DOCUMENT 0001759425 2022-03-09 2022-03-09 0001759425 false 8-K 2022-03-09 Mirum Pharmaceuticals, Inc. DE 001-38981 83-1281555 950 Tower Lane Suite 1050 Foster City CA 94404 650 667-4085 N/A false false false false Common stock, par value $0.0001 per share MIRM NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports mirm-20220309.htm mirm-20220309.xsd mirm-20220309_lab.xml mirm-20220309_pre.xml mirm-ex99_1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mirm-20220309.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml" ] }, "inline": { "local": [ "mirm-20220309.htm" ] }, "labelLink": { "local": [ "mirm-20220309_lab.xml" ] }, "presentationLink": { "local": [ "mirm-20220309_pre.xml" ] }, "schema": { "local": [ "mirm-20220309.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mirm", "nsuri": "http://mirumpharma.com/20220309", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "mirm-20220309.htm", "contextRef": "C_cd8e0ef6-7e1a-4885-a84c-4448ab18f741", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "mirm-20220309.htm", "contextRef": "C_cd8e0ef6-7e1a-4885-a84c-4448ab18f741", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://mirumpharma.com/20220309/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0000950170-22-003222-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-003222-xbrl.zip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̝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